US · Healthcare · Biotechnology
EPS came in at 0.47 against a street estimate of -0.44 — a beat of 206.8%.
Analysts rate enGene Holdings Inc. Common Stock a hold (3 buy, 6 hold, 1 sell out of 10) with an average price target of $3.29.
| Fund | Stake |
|---|---|
| BML Capital Management LLC | 9.95% |
| Siren, L.L.C. | 9.34% |
| Perceptive Advisors LLC | 7.20% |
| Columbia Mgmt Investment Advisers, LLC | 3.99% |
| Nextech Invest, Ltd. | 3.47% |
| ADAR1 Capital Management LLC | 3.14% |
| Vestal Point Capital LP | 2.49% |
| Peapod Lane Capital LLC | 1.64% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for enGene Holdings Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.